gip glp 1 agonist Understand GLP-1/GIP Dual Tirzepatide and Its Effect on Current Weight Loss Therapy New strategies for the treatment
Description
Why the hype: Diabetes, obesity, and vascular disease are known contributors to brain aging and dementia risk
The study has several important caveats
Sitagliptin was approved in 2006, but in contrast to the GLP-1 agonists, DPP4 inhibitors have little or no effect on body weight
In conclusion, our real-world study demonstrates that the use of GLP-1 RAs may not be associated with an increased risk of mood/behavior disorders, including depression, anxiety, and suicidal behavior
Rates of NAION were even higher among young men with a history of smoking
doi:10.1016/j.bbrc.2014.03.004 52
